Literature DB >> 8593026

Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression.

P K Peterson1, G Gekker, M Bornemann, D Chatterjee, C C Chao.   

Abstract

Mycobacterium tuberculosis accelerates the progression of human immunodeficiency virus type 1 (HIV-1) infection. The results of this study, which show that thalidomide inhibits the upregulation of HIV-1 expression in U1 cells stimulated with mycobacterial lipoarabinomannans, support the rationale behind conducting controlled trials of this immunodeficiency agent with patients dually infected with HIV-1 and M. tuberculosis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8593026      PMCID： PMC163036          DOI： 10.1128/AAC.39.12.2807

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor.

Authors:  D Chatterjee; A D Roberts; K Lowell; P J Brennan; I M Orme
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  AIDS two months after primary human immunodeficiency virus infection.

Authors:  B Isaksson; J Albert; F Chiodi; A Furucrona; A Krook; P Putkonen
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 3.  The effect of cytokines and pharmacologic agents on chronic HIV infection.

Authors:  G Poli; A S Fauci
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

4.  Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components.

Authors:  Y Zhang; M Doerfler; T C Lee; B Guillemin; W N Rom
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.

Authors:  J W Pape; S S Jean; J L Ho; A Hafner; W D Johnson
Journal:  Lancet       Date:  1993-07-31       Impact factor: 79.321

6.  Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Authors:  S Makonkawkeyoon; R N Limson-Pobre; A L Moreira; V Schauf; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  Microglial cell upregulation of HIV-1 expression in the chronically infected promonocytic cell line U1: the role of tumor necrosis factor-alpha.

Authors:  P K Peterson; G Gekker; S Hu; Y Schoolov; H H Balfour; C C Chao
Journal:  J Neuroimmunol       Date:  1992-11       Impact factor: 3.478

8.  Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis.

Authors:  R S Wallis; M Vjecha; M Amir-Tahmasseb; A Okwera; F Byekwaso; S Nyole; S Kabengera; R D Mugerwa; J J Ellner
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

9.  Human immunodeficiency virus and Mycobacterium avium complex coinfection of monocytoid cells results in reciprocal enhancement of multiplication.

Authors:  M Ghassemi; B R Andersen; V M Reddy; P R Gangadharam; G T Spear; R M Novak
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

10.  Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1.

Authors:  Z Toossi; J G Sierra-Madero; R A Blinkhorn; M A Mettler; E A Rich
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307
View more
  2 in total

Review 1.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication.

Authors:  D Wolday; H Akuffo; A Demissie; S Britton
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.